Your browser doesn't support javascript.
loading
Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.
Zago, Elisa; Dal Molin, Alessandra; Dimitri, Giovanna Maria; Xumerle, Luciano; Pirazzini, Chiara; Bacalini, Maria Giulia; Maturo, Maria Giovanna; Azevedo, Tiago; Spasov, Simeon; Gómez-Garre, Pilar; Periñán, María Teresa; Jesús, Silvia; Baldelli, Luca; Sambati, Luisa; Calandra-Buonaura, Giovanna; Garagnani, Paolo; Provini, Federica; Cortelli, Pietro; Mir, Pablo; Trenkwalder, Claudia; Mollenhauer, Brit; Franceschi, Claudio; Liò, Pietro; Nardini, Christine.
  • Zago E; Personal Genomics S.R.L., Verona, Italy.
  • Dal Molin A; Personal Genomics S.R.L., Verona, Italy.
  • Dimitri GM; Computer Laboratory, Department of Computer Science and Technology, University of Cambridge, Cambridge, UK.
  • Xumerle L; Personal Genomics S.R.L., Verona, Italy.
  • Pirazzini C; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Bacalini MG; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Maturo MG; Personal Genomics S.R.L., Verona, Italy.
  • Azevedo T; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Spasov S; Computer Laboratory, Department of Computer Science and Technology, University of Cambridge, Cambridge, UK.
  • Gómez-Garre P; Computer Laboratory, Department of Computer Science and Technology, University of Cambridge, Cambridge, UK.
  • Periñán MT; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Jesús S; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Baldelli L; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Sambati L; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Calandra-Buonaura G; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Garagnani P; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Provini F; Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
  • Cortelli P; Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
  • Mir P; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Trenkwalder C; Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
  • Mollenhauer B; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Franceschi C; Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Liò P; Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden.
  • Nardini C; Alma Mater Research Institute on Global Challenges and Climate Change (Alma Climate), University of Bologna, Bologna, Italy.
Sci Rep ; 12(1): 1330, 2022 01 25.
Article en En | MEDLINE | ID: mdl-35079043
ABSTRACT
Advanced age represents one of the major risk factors for Parkinson's Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson's Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson's Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson's Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson's Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson's Disease patients, and healthy siblings of Parkinson's Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson's Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson's Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson's Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson's Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson's Disease.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Envejecimiento / MicroARNs Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Envejecimiento / MicroARNs Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article